Vito Annese
A5023173269- Inflammatory Bowel Disease
- Microscopic Colitis
- Helicobacter pylori-related gastroenterology studies
- Gastroesophageal reflux and treatments
- Eosinophilic Esophagitis
- Esophageal and GI Pathology
- Immunodeficiency and Autoimmune Disorders
- Celiac Disease Research and Management
- Liver Diseases and Immunity
- Gastrointestinal motility and disorders
- Gastric Cancer Management and Outcomes
- Dysphagia Assessment and Management
- Autoimmune and Inflammatory Disorders
- IL-33, ST2, and ILC Pathways
- Esophageal Cancer Research and Treatment
- Liver Disease Diagnosis and Treatment
- Biosimilars and Bioanalytical Methods
- Gastrointestinal disorders and treatments
- Genetic factors in colorectal cancer
- Pregnancy and Medication Impact
- Systemic Lupus Erythematosus Research
- Diet and metabolism studies
- Digestive system and related health
- Galectins and Cancer Biology
- Tuberculosis Research and Epidemiology
IRCCS Policlinico San Donato
2005-2025
Vita-Salute San Raffaele University
2023-2025
University of Pisa
2024
University of Pavia
2024
IRCCS Ospedale San Raffaele
2024
Azienda Ospedaliero-Universitaria Careggi
2012-2023
Casa Sollievo della Sofferenza
2009-2023
Istituti di Ricovero e Cura a Carattere Scientifico
2009-2023
Dubai Hospital
2017-2023
Alessandro Manzoni Hospital
2022
This paper is the first in a series of two publications relating to European Crohn's and Colitis Organisation [ECCO] evidence-based consensus on diagnosis management disease concerns methodology process, classification, medical active quiescent disease. Surgical as well special situations including perianal this ECCO Consensus are covered subsequent second [Gionchetti et al JCC 2016].
Many experts consider laparoscopic Heller's myotomy (LHM) to be superior pneumatic dilation for the treatment of achalasia, and LHM is increasingly considered choice this disorder.We randomly assigned patients with newly diagnosed achalasia or Dor's fundoplication. Symptoms, including weight loss, dysphagia, retrosternal pain, regurgitation, were assessed use Eckardt score (which ranges from 0 12, higher scores indicating more pronounced symptoms). The primary outcome was therapeutic success...
Endoscopy plays an essential role in the diagnosis, management, prognosis, and surveillance of inflammatory bowel disease (IBD), but surprisingly there are few available guidelines.1,2 This prompted ECCO Guidelines Committee (GuiCom) members to promote a Consensus on appropriate indication application different endoscopic modalities IBD. Since development guidelines is expensive time-consuming process, this may help avoid duplication effort future. It also identify issues where evidence...
This is the first European Crohn’s and Colitis Organisation [ECCO] consensus guideline that addresses extra-intestinal manifestations [EIMs] in inflammatory bowel disease [IBD]. It has been drafted by 21 ECCO members from 13 countries. Although this primarily EIMs, it partly derived from, updates, replaces previous advice on contained within guidelines for disease1 [CD] ulcerative colitis2 [UC]. The strategy to define was similar previously described other [available at www.ecco-ibd.eu]....
Crohn's disease and ulcerative colitis are the two major forms of inflammatory bowel disease; treatment strategies have historically been determined by this binary categorisation. Genetic studies identified 163 susceptibility loci for disease, mostly shared between colitis. We undertook largest genotype association study, to date, in widely used clinical subphenotypes with goal further understanding biological relations diseases.
VSL#3 is a high-potency probiotic mixture that has been used successfully in the treatment of pouchitis. The primary end point study was to assess effects supplementation with patients affected by relapsing ulcerative colitis (UC) who are already under 5-aminosalicylic acid (ASA) and/or immunosuppressants at stable doses.A total 144 consecutive were randomly treated for 8 weeks dose 3,600 billion CFU/day (71 patients) or placebo (73 patients).In all, 65 group and 66 completed study. decrease...
This is the second of a series two articles reporting European Crohn's and Colitis Organisation [ECCO] evidence-based consensus on management adult patients with ulcerative colitis [UC]. The first article focused medical management, present addresses treatment acute severe [ASUC] surgical medically refractory UC patients, including preoperative optimisation, strategies, technical issues. provides advice for variety common clinical conditions. Together, represent an update recommendations ECCO UC.
than non-IBD CRC patients, but they survived about 3 years longer.Older age, male sex, smoking, and advanced grade stage were independently associated with shorter survival times.When propensity score matching was used to analyse outcomes, the times of patients without IBD not significantly different. 16Taken together, these results reveal that tend develop at younger ages patients.However, no effect on patient has been consistently demonstrated.
<h3>Objective</h3> Achalasia is a chronic motility disorder of the oesophagus for which laparoscopic Heller myotomy (LHM) and endoscopic pneumodilation (PD) are most commonly used treatments. However, prospective data comparing their long-term efficacy lacking. <h3>Design</h3> 201 newly diagnosed patients with achalasia were randomly assigned to PD (n=96) or LHM (n=105). Before randomisation, symptoms assessed using Eckardt score, functional test performed quality life was assessed. The...
Chapter 4: Scores for Inflammatory Bowel Disease 4.1 Clinical and endoscopic scoring systems in IBD Statement 4.1.ECCO-ESGAR Diagnostics GL (2018) indices are useful standardizing disease activity.However, despite widespread use, no score has been validated clinical practice [EL5] ulcerative colitisThere several presently available to classify severity colitis (UC) within the multiple domains of activity, which aid objective assessment guide therapeutic monitoring strategies [1,2].Although...
Background & AimsMost patients with Crohn's disease (CD) eventually require an intestinal resection. However, CD frequently recurs after We performed a randomized trial to compare the ability of infliximab vs placebo prevent recurrence.MethodsWe evaluated efficacy in preventing postoperative recurrence 297 at 104 sites worldwide from November 2010 through May 2012. All study had undergone ileocolonic resection within 45 days before randomization. Patients were randomly assigned (1:1) groups...